Submit or Track your Manuscript LOG-IN

Clinical Study on Ulinastatin Combined with Ambroxol in the Treatment of AECOPD Complicated with Type II Respiratory Failure

Clinical Study on Ulinastatin Combined with Ambroxol in the Treatment of AECOPD Complicated with Type II Respiratory Failure

Xia Li1*, Xueliang Zhan1 and Xinjie Shi2

1Emergency Internal Medicine Department of Weihai Central Hospital, Weihai, 264400, China
2Department of Respiratory Medicine, Weihai Central Hospital, Weihai, 264400, China

*      Corresponding author: prof.xia.Li@gmail.com

ABSTRACT

The Objective of the present study was to observe and analyze the efficacy of ulinastatin combined with ambroxol in the treatment of AECOPD complicated with type II respiratory failure. A total of 180 patients treated in our hospital due to AECOPD complicated with type II respiratory failure were enrolled in the study and divided into study group and reference group, each with 90 patients. The study group was treated with ulinastatin and ambroxol, while general routine treatment was implemented in the reference group. The treatment outcomes were compared between the two groups. The blood content levels of WBC, CRP and PCT were compared between the two groups after one week of treatment. The results showed that the improvement effect was significantly superior in the study group, p<0.05. The arterial blood gas analysis showed that the arterial blood PO2 was elevated and PCO2 was decreased in the study group. The difference was statistically significant (P<0.05). It was concluded that the application of ulinastatin combined with ambroxol in the treatment of AECOPD complicated with type II respiratory failure can significantly improve the treatment effect, help patients actively improve the condition and promote body recovery as soon as possible.
 

To share on other social networks, click on P-share. What are these?

Pakistan Journal of Zoology

February

Vol. 53, Iss. 1, Pages 1-400

Featuring

Click here for more

Subscribe Today

Receive free updates on new articles, opportunities and benefits


Subscribe Unsubscribe